A phase 2 study of vatalanib in metastatic melanoma patients. (2010)
Attributed to:
Hub in Trials Methodology Research (MRC Biostatistics Unit, Cambridge)
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.ejca.2010.07.014
PubMed Identifier: 20800475
Publication URI: http://europepmc.org/abstract/MED/20800475
Type: Journal Article/Review
Volume: 46
Parent Publication: European journal of cancer (Oxford, England : 1990)
Issue: 15
ISSN: 0959-8049